Trial
NCT02818023
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Yana Najjar
Collaborators
Merck Sharp & Dohme LLC
Condition
Melanoma
Intervention
Pembrolizumab
Why stopped
Accrual to trial stopped due to high toxicity even at lowest dose of combination treatment. Patients on trial tolerating treatment at time of accrual closure still continued to receive treatment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-03